Our underlying platform technologies, RespirVec™ and Densigen™, are versatile and have potential applicability in a wide range of immunotherapeutic approaches to treat disease. These two platform technologies represent distinct, complementary and potentially synergistic approaches to engaging and improving the immune response. We are developing candidates based on these technologies that are designed to recruit or stimulate the appropriate elements of the human immune system to treat a given disease indication. We are currently applying our technologies to respiratory diseases, chronic infections and cancer. We will also opportunistically continue to apply our technologies to areas of national security or public interest where government funding is available for such projects.